Viridian's Two-Front War on Thyroid Eye Disease Nears Climax

WALTHAM, Mass. – February 26, 2026 – Viridian Therapeutics is on the precipice of a company-defining year, armed with a dual-pronged strategy aimed at disrupting the multi-billion dollar market for Thyroid Eye Disease (TED). The biotechnology firm recently detailed its aggressive push, highlighting a looming FDA decision for its lead drug, veligrotug, and imminent pivotal data for a second, potentially best-in-class subcutaneous therapy, elegrobart. This clinical momentum is set against a backdrop of significant investment, as the company's year-end financial results reveal a surge in spending to build out commercial operations and advance a diversifying pipeline.

"We enter 2026 with the momentum of our continued execution,” said Steve Mahoney, President and Chief Executive Officer of Viridian, in a statement. “Our goal is to establish veligrotug and elegrobart as foundational therapies for TED, while driving our pipeline forward to address additional indications and unmet needs.”

A Dual Offensive to Redefine TED Treatment

Viridian's primary focus is on capturing a significant share of the lucrative TED market, which was valued at over $2.8 billion in 2025 and is projected to exceed $4 billion by the early 2030s. The current landscape is dominated by Amgen's Tepezza, an intravenous therapy that set a new standard of care upon its approval. Viridian aims to challenge this dominance not with one, but two distinct therapeutic options.

The first wave of this offensive is veligrotug, an intravenous anti-IGF-1R antibody. The treatment is currently under Priority Review with the U.S. Food and Drug Administration (FDA), with a decision on its Biologics License Application (BLA) expected by its PDUFA target date of June 30, 2026. A Priority Review designation shortens the regulatory timeline, underscoring the FDA's belief that the drug, if approved, could offer a significant improvement over existing options. The application is supported by robust Phase 3 data from the THRIVE and THRIVE-2 trials, which demonstrated rapid and meaningful improvements in both active and chronic TED patients. If approved, Viridian is planning for a mid-2026 U.S. launch and has also submitted for approval in Europe, signaling its global ambitions.

While veligrotug aims to compete directly in the intravenous space, Viridian’s second candidate, elegrobart, represents a strategic move toward patient convenience. Designed as an infrequent, low-volume, at-home subcutaneous injection, elegrobart could fundamentally shift the treatment paradigm away from hospital-based infusions. The therapy, which has an engineered half-life four to five times longer than veligrotug, is being studied with dosing schedules of every four or even every eight weeks.

The entire biotech community is now watching for topline data from its two pivotal Phase 3 trials. Results from REVEAL-1 in active TED are expected by the end of this quarter, with data from REVEAL-2 in chronic TED—the largest global Phase 3 trial in the disease to date—anticipated in the second quarter of 2026. Positive outcomes from these trials could solidify elegrobart's position as a best-in-class subcutaneous option and provide patients and physicians with unprecedented flexibility.

The Financial Realities of Building a Commercial Powerhouse

This ambitious clinical and commercial strategy comes at a significant cost. Viridian’s 2025 financial report underscores the heavy investment required to transition from a development-stage company to a commercial entity. The company reported a net loss of $342.6 million for 2025, a substantial increase from the $269.9 million loss in 2024.

The spending surge is concentrated in two key areas. Research and development (R&D) expenses climbed to $338.9 million, fueled by the large-scale pivotal trials for its TED portfolio and investments in its earlier-stage programs. Simultaneously, Selling, General, and Administrative (SG&A) expenses grew to $95.3 million as the company aggressively builds its commercial infrastructure. This includes hiring field leadership, sales representatives, and market access teams in preparation for veligrotug's potential launch this summer.

Despite the high burn rate, Viridian stands on solid financial ground. The company ended 2025 with a robust cash position of $874.7 million. Management expressed confidence that this cash, combined with potential milestone payments and future revenues from its TED franchise, will be sufficient to fund operations through to profitability. However, the path to commercial success is capital-intensive, and the company's ability to manage its burn rate while executing a successful product launch will be a key factor for investors to monitor throughout 2026.

Expanding Horizons Beyond Thyroid Eye Disease

While TED remains its immediate focus, Viridian is strategically building a long-term growth engine by diversifying into other serious autoimmune and rare diseases. The company is leveraging its expertise in antibody engineering to develop a pipeline of novel therapies targeting validated biological pathways.

A key part of this strategy is its portfolio of neonatal Fc receptor (FcRn) inhibitors. The FcRn pathway is a clinically validated target for treating a wide range of diseases driven by pathogenic IgG autoantibodies. Viridian is advancing two candidates in this competitive space. The first, VRDN-006, has already shown positive proof-of-concept data in a Phase 1 trial. The second, VRDN-008, is a next-generation candidate designed with an extended half-life for more sustained IgG suppression. A Phase 1 trial for VRDN-008 is now underway, with initial data expected in the second half of 2026. These programs place Viridian in a dynamic field alongside major players like Argenx and UCB, but it hopes to differentiate its offerings with more convenient, self-administered subcutaneous options.

Further diversifying its portfolio, the company is also developing a monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR). This program is designed to treat not only the symptoms of TED but also the underlying autoimmune condition, Graves’ disease. Viridian plans to submit an Investigational New Drug (IND) application for this program in late 2026, opening another potential front in its mission to address unmet needs in autoimmune disorders. As the company awaits its first potential product approval, these early-stage assets represent significant future value and underscore a long-term vision that extends far beyond its initial targets.